Docoh
Loading...

IGMS IGM Biosciences

News

From Benzinga Pro
12 Health Care Stocks Moving In Friday's Intraday Session
26 Nov 21
Intraday Update, Markets, Movers
92 Biggest Movers From Friday
8 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Friday's Intraday Session
5 Nov 21
Intraday Update, Markets, Movers
64 Stocks Moving In Friday's Mid-Day Session
5 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the estimated price range of $4-$6, for raising gross proceeds of $10 million.
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
5 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
RBC Capital Maintains Outperform on IGM Biosciences, Lowers Price Target to $90
5 Nov 21
News, Price Target, Analyst Ratings
RBC Capital analyst Brian Abrahams maintains IGM Biosciences (NASDAQ:IGMS) with a Outperform and lowers the price target from $110 to $90.
Wedbush Upgrades IGM Biosciences to Outperform, Announces $82 Price Target
5 Nov 21
News, Upgrades, Price Target, Analyst Ratings
Wedbush analyst Robert Driscoll upgrades IGM Biosciences (NASDAQ:IGMS) from Neutral to Outperform and announces $82 price target.
IGM Biosciences Q3 EPS $(1.32) Down From $(0.66) YoY
4 Nov 21
Earnings, News
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.32) per share. This is a 100 percent decrease over losses of $(0.66) per share from the same period last year.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11)
IGM Biosciences Reports Formation Of 2 Business Units: IGM Infectious Diseases, IGM Autoimmunity And Inflammation
11 Oct 21
News, Management
IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and

Press releases

From Benzinga Pro
IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 63rd Annual ASH Meeting
6 Dec 21
News, Press Releases
MOUNTAIN VIEW, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that
Medivir to present at the Erik Penser Bank Life Science Day
1 Dec 21
Press Releases
STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Erik Penser Bank Life Science Day, Thursday December 2, 2021. The presentation will be
Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published
18 Nov 21
Press Releases
STOCKHOLM, Nov. 18, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC) has been
Medivir to present at the Redeye Life Science Day
11 Nov 21
Press Releases
STOCKHOLM, Nov. 11, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Life Science Day, at 1pm CET today, November 11, 2021. The presentation is live
Birinapant clinical study initiated by IGM Biosciences
4 Nov 21
Small Cap, Press Releases
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid cancers with birinapant (a k a IGM-9427) in combination with
IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update
4 Nov 21
Earnings, Press Releases
– Plans to Initiate Phase 2 Studies of IGM-2323 in Diffuse Large B-cell Lymphoma and Follicular Lymphoma – – Data from IGM-2323 Selected for Oral Presentation at 2021 ASH Annual Meeting – – IGM-8444 Successfully
Nomination Committee of Medivir appointed
28 Oct 21
Press Releases
STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2022. According to an AGM
Medivir Appoints Jens Lindberg as Chief Executive Officer
25 Oct 21
Press Releases
STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the
A joint patent application for MALT1 inhibitors published
15 Oct 21
Press Releases
STOCKHOLM, Oct. 15, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that a joint patent application for MALT1 inhibitors submitted together with Rheos Medicines, Inc., a US-based
IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business Units
11 Oct 21
News, Management, Press Releases
– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases – – Mary Beth Harler, M.D., Appointed as President of IGM
Medivir to present at the ProHearings shared Capital Markets Day
11 Oct 21
Small Cap, Press Releases
STOCKHOLM, Oct. 11, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets Day, October 14, 2021. The presentation will be
IGM Biosciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
23 Sep 21
News, Press Releases
MOUNTAIN VIEW, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that
Medivir invites to a conference call on new clinical data and further studies with MIV-818
16 Sep 21
Press Releases
STOCKHOLM, Sept. 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed dose escalation section of the phase 1b study with MIV-818,
Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published
13 Sep 21
Press Releases
STOCKHOLM, Sept. 13, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled "Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC),
Medivir to present at the Wainwright Annual Global Investment Conference
10 Sep 21
Press Releases
STOCKHOLM, Sept. 10, 2021 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright Annual Global Investment Conference, September 13-15. The